Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Scientific Advisory Board

ALQGC: FRESH Results in November

By John Vandermosten, CFA EPA:ALQGC READ THE FULL ALQGC RESEARCH REPORT

Recap Of Tuesday's Biotech Catalysts - End of The Day Summary

Recap Of Tuesday's Biotech Catalysts - End of The Day Summary

European Commission (EC) has approved AbbVie’s (NYSE:ABBV) lead asset RINVOQ (upadacitinib 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) for the treatment of adult patients with moderately to severely active ulcerative colitis. AbbVie shares traded in a range of $150.33 to $153.56 on a day volume…

BCTX: New Sites Expand Bria-IMT Trial

By John Vandermosten, CFA NASDAQ:BCTX READ THE FULL BCTX RESEARCH REPORT

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Pfizer Injects $25M Via Equity In Zentalis Pharma

Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) will sell 953,834 common shares at $26.21 per share to Pfizer Inc (NYSE:PFE) for $25 million. The offering is expected to close by April 29. Zentalis will use the proceeds to fund ongoing and planned clinical trials, including studies of ZN-c3 and ZN-d5, and for working capital and general corporate…

1

People

John Vandermosten

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

European Commission

Medicines and Healthcare products Regulatory Agency

BridgeBio Pharma

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Sickle Cell Disease

Ulcerative Colitis

Macular Degeneration

Amyotrophic lateral sclerosis

Places

144,535 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play